Managed Healthcare Executive December 5, 2024
Psilocybin-assisted therapy, which involves using the active ingredient from “magic mushrooms,” could benefit roughly 5 million people currently receiving treatment for major depressive disorder and treatment-resistant depression if the FDA approves it.
Psilocybin-assisted therapy (PSIL-AT), which involves using the active ingredient from “magic mushrooms,” could benefit roughly 5 million people currently receiving treatment for major depressive disorder (MDD) and treatment-resistant depression (TRD) if the FDA approves it, according to a new study from Emory University.
Psilocybin is currently FDA approved only for use in clinical trials to study its safety and efficacy. However, it’s not yet approved for treating any conditions outside of these trials, including major depressive disorder and treatment-resistant depression.
major depressive disorder is a common mental health...
Today's Sponsors
Today's Sponsor